nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—NTRK1—malignant glioma	0.296	0.473	CbGaD
Imatinib—PDGFRA—malignant glioma	0.246	0.392	CbGaD
Imatinib—PTGS1—malignant glioma	0.0855	0.136	CbGaD
Imatinib—CYP1A2—Carmustine—malignant glioma	0.023	0.57	CbGbCtD
Imatinib—CYP3A4—Temozolomide—malignant glioma	0.0174	0.431	CbGbCtD
Imatinib—Edema cerebral—Carmustine—malignant glioma	0.00416	0.0393	CcSEcCtD
Imatinib—Edema cerebral—Temozolomide—malignant glioma	0.00402	0.038	CcSEcCtD
Imatinib—ORM1—vertebral column—malignant glioma	0.00239	0.0346	CbGeAlD
Imatinib—Brain oedema—Carmustine—malignant glioma	0.00225	0.0213	CcSEcCtD
Imatinib—Brain oedema—Temozolomide—malignant glioma	0.00218	0.0206	CcSEcCtD
Imatinib—Retinal haemorrhage—Carmustine—malignant glioma	0.00197	0.0187	CcSEcCtD
Imatinib—Pigmentation disorder—Temozolomide—malignant glioma	0.00186	0.0176	CcSEcCtD
Imatinib—ABCA3—telencephalon—malignant glioma	0.00156	0.0226	CbGeAlD
Imatinib—Intracranial pressure increased—Carmustine—malignant glioma	0.00154	0.0146	CcSEcCtD
Imatinib—Ponatinib—FGFR1—malignant glioma	0.00154	0.266	CrCbGaD
Imatinib—Pulmonary fibrosis—Carmustine—malignant glioma	0.00146	0.0138	CcSEcCtD
Imatinib—DDR1—telencephalon—malignant glioma	0.00144	0.0208	CbGeAlD
Imatinib—NTRK1—midbrain—malignant glioma	0.00142	0.0205	CbGeAlD
Imatinib—Pulmonary fibrosis—Temozolomide—malignant glioma	0.00141	0.0134	CcSEcCtD
Imatinib—Myelosuppression—Carmustine—malignant glioma	0.00137	0.013	CcSEcCtD
Imatinib—Myelosuppression—Temozolomide—malignant glioma	0.00133	0.0125	CcSEcCtD
Imatinib—Interstitial pneumonia—Temozolomide—malignant glioma	0.00129	0.0122	CcSEcCtD
Imatinib—ABCA3—medulla oblongata—malignant glioma	0.00122	0.0177	CbGeAlD
Imatinib—Lymphopenia—Temozolomide—malignant glioma	0.00121	0.0115	CcSEcCtD
Imatinib—Ponatinib—PDGFRA—malignant glioma	0.00119	0.205	CrCbGaD
Imatinib—KIT—endothelium—malignant glioma	0.00116	0.0168	CbGeAlD
Imatinib—Cerebral haemorrhage—Carmustine—malignant glioma	0.00116	0.011	CcSEcCtD
Imatinib—DDR1—medulla oblongata—malignant glioma	0.00113	0.0164	CbGeAlD
Imatinib—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00112	0.0106	CcSEcCtD
Imatinib—ABCA3—midbrain—malignant glioma	0.00112	0.0162	CbGeAlD
Imatinib—ABCA3—spinal cord—malignant glioma	0.00109	0.0158	CbGeAlD
Imatinib—Skin hyperpigmentation—Carmustine—malignant glioma	0.00108	0.0102	CcSEcCtD
Imatinib—KIT—blood vessel—malignant glioma	0.00107	0.0155	CbGeAlD
Imatinib—Febrile neutropenia—Carmustine—malignant glioma	0.00107	0.0101	CcSEcCtD
Imatinib—PDGFRB—blood vessel—malignant glioma	0.00105	0.0152	CbGeAlD
Imatinib—Febrile neutropenia—Temozolomide—malignant glioma	0.00103	0.00978	CcSEcCtD
Imatinib—DDR1—midbrain—malignant glioma	0.00103	0.015	CbGeAlD
Imatinib—DDR1—spinal cord—malignant glioma	0.00101	0.0146	CbGeAlD
Imatinib—Embolism—Temozolomide—malignant glioma	0.000968	0.00916	CcSEcCtD
Imatinib—PIP4K2C—retina—malignant glioma	0.000965	0.014	CbGeAlD
Imatinib—Cyst—Carmustine—malignant glioma	0.000962	0.0091	CcSEcCtD
Imatinib—Digestion impaired—Temozolomide—malignant glioma	0.00093	0.0088	CcSEcCtD
Imatinib—Ponatinib—KDR—malignant glioma	0.000922	0.159	CrCbGaD
Imatinib—Thrombosis—Carmustine—malignant glioma	0.000909	0.0086	CcSEcCtD
Imatinib—Interstitial lung disease—Carmustine—malignant glioma	0.000909	0.0086	CcSEcCtD
Imatinib—PIP4K2C—telencephalon—malignant glioma	0.000888	0.0129	CbGeAlD
Imatinib—Myopathy—Temozolomide—malignant glioma	0.000886	0.00839	CcSEcCtD
Imatinib—ABCA3—central nervous system—malignant glioma	0.000886	0.0128	CbGeAlD
Imatinib—Interstitial lung disease—Temozolomide—malignant glioma	0.000878	0.00831	CcSEcCtD
Imatinib—Nilotinib—PDGFRA—malignant glioma	0.000875	0.151	CrCbGaD
Imatinib—ABCA3—cerebellum—malignant glioma	0.000866	0.0125	CbGeAlD
Imatinib—CA3—telencephalon—malignant glioma	0.000848	0.0123	CbGeAlD
Imatinib—Menorrhagia—Temozolomide—malignant glioma	0.00084	0.00795	CcSEcCtD
Imatinib—Hepatotoxicity—Carmustine—malignant glioma	0.000833	0.00788	CcSEcCtD
Imatinib—Herpes zoster—Temozolomide—malignant glioma	0.000826	0.00781	CcSEcCtD
Imatinib—Necrosis—Carmustine—malignant glioma	0.00082	0.00775	CcSEcCtD
Imatinib—Hepatotoxicity—Temozolomide—malignant glioma	0.000805	0.00762	CcSEcCtD
Imatinib—Nilotinib—BRAF—malignant glioma	0.0008	0.138	CrCbGaD
Imatinib—PDGFRA—embryo—malignant glioma	0.0008	0.0116	CbGeAlD
Imatinib—DDR1—cerebellum—malignant glioma	0.000799	0.0116	CbGeAlD
Imatinib—Hyperaesthesia—Temozolomide—malignant glioma	0.000792	0.00749	CcSEcCtD
Imatinib—Memory impairment—Temozolomide—malignant glioma	0.000792	0.00749	CcSEcCtD
Imatinib—CA14—telencephalon—malignant glioma	0.00077	0.0111	CbGeAlD
Imatinib—Rigors—Temozolomide—malignant glioma	0.000761	0.0072	CcSEcCtD
Imatinib—Petechiae—Temozolomide—malignant glioma	0.000756	0.00715	CcSEcCtD
Imatinib—NQO2—brainstem—malignant glioma	0.000735	0.0106	CbGeAlD
Imatinib—HIPK4—brain—malignant glioma	0.000711	0.0103	CbGeAlD
Imatinib—CSF1R—embryo—malignant glioma	0.000704	0.0102	CbGeAlD
Imatinib—ABCA3—brain—malignant glioma	0.000703	0.0102	CbGeAlD
Imatinib—PIP4K2C—medulla oblongata—malignant glioma	0.000698	0.0101	CbGeAlD
Imatinib—Drug interaction—Carmustine—malignant glioma	0.000693	0.00656	CcSEcCtD
Imatinib—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000684	0.00647	CcSEcCtD
Imatinib—Herpes simplex—Temozolomide—malignant glioma	0.000675	0.00638	CcSEcCtD
Imatinib—CA7—midbrain—malignant glioma	0.000664	0.00961	CbGeAlD
Imatinib—Hearing impaired—Temozolomide—malignant glioma	0.000653	0.00618	CcSEcCtD
Imatinib—NQO2—telencephalon—malignant glioma	0.000652	0.00944	CbGeAlD
Imatinib—PDGFRA—telencephalon—malignant glioma	0.00065	0.00942	CbGeAlD
Imatinib—DDR1—brain—malignant glioma	0.000649	0.0094	CbGeAlD
Imatinib—KIT—embryo—malignant glioma	0.000639	0.00926	CbGeAlD
Imatinib—PIP4K2C—midbrain—malignant glioma	0.000638	0.00923	CbGeAlD
Imatinib—Musculoskeletal pain—Temozolomide—malignant glioma	0.000629	0.00595	CcSEcCtD
Imatinib—PDGFRB—embryo—malignant glioma	0.000624	0.00904	CbGeAlD
Imatinib—PIP4K2C—spinal cord—malignant glioma	0.000622	0.00901	CbGeAlD
Imatinib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000622	0.00588	CcSEcCtD
Imatinib—Skin exfoliation—Carmustine—malignant glioma	0.000614	0.00581	CcSEcCtD
Imatinib—CA14—medulla oblongata—malignant glioma	0.000605	0.00876	CbGeAlD
Imatinib—Influenza like illness—Temozolomide—malignant glioma	0.000604	0.00571	CcSEcCtD
Imatinib—CA12—telencephalon—malignant glioma	0.0006	0.00869	CbGeAlD
Imatinib—Skin exfoliation—Temozolomide—malignant glioma	0.000594	0.00561	CcSEcCtD
Imatinib—SLC47A1—brainstem—malignant glioma	0.000589	0.00853	CbGeAlD
Imatinib—KIT—brainstem—malignant glioma	0.000586	0.00848	CbGeAlD
Imatinib—Aplastic anaemia—Temozolomide—malignant glioma	0.000584	0.00552	CcSEcCtD
Imatinib—Neoplasm—Carmustine—malignant glioma	0.000582	0.0055	CcSEcCtD
Imatinib—Gynaecomastia—Carmustine—malignant glioma	0.000576	0.00544	CcSEcCtD
Imatinib—Dry eye—Temozolomide—malignant glioma	0.000574	0.00543	CcSEcCtD
Imatinib—CSF1R—telencephalon—malignant glioma	0.000573	0.00829	CbGeAlD
Imatinib—Neoplasm—Temozolomide—malignant glioma	0.000562	0.00532	CcSEcCtD
Imatinib—Sepsis—Carmustine—malignant glioma	0.000558	0.00528	CcSEcCtD
Imatinib—ABL1—embryo—malignant glioma	0.000557	0.00806	CbGeAlD
Imatinib—CA14—midbrain—malignant glioma	0.000553	0.008	CbGeAlD
Imatinib—CA14—spinal cord—malignant glioma	0.000539	0.00781	CbGeAlD
Imatinib—PTGS1—endothelium—malignant glioma	0.000532	0.0077	CbGeAlD
Imatinib—ABL2—cerebellum—malignant glioma	0.000521	0.00755	CbGeAlD
Imatinib—KIT—telencephalon—malignant glioma	0.00052	0.00753	CbGeAlD
Imatinib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000519	0.00491	CcSEcCtD
Imatinib—Eye pain—Carmustine—malignant glioma	0.000517	0.00489	CcSEcCtD
Imatinib—CA7—cerebellum—malignant glioma	0.000513	0.00743	CbGeAlD
Imatinib—NQO2—medulla oblongata—malignant glioma	0.000512	0.00742	CbGeAlD
Imatinib—ABL1—brainstem—malignant glioma	0.00051	0.00738	CbGeAlD
Imatinib—Gastroenteritis—Temozolomide—malignant glioma	0.000509	0.00482	CcSEcCtD
Imatinib—PDGFRB—telencephalon—malignant glioma	0.000508	0.00735	CbGeAlD
Imatinib—PIP4K2C—central nervous system—malignant glioma	0.000505	0.00731	CbGeAlD
Imatinib—Deafness—Temozolomide—malignant glioma	0.000504	0.00477	CcSEcCtD
Imatinib—Vascular purpura—Temozolomide—malignant glioma	0.000504	0.00477	CcSEcCtD
Imatinib—Hepatic failure—Temozolomide—malignant glioma	0.000502	0.00475	CcSEcCtD
Imatinib—Eye pain—Temozolomide—malignant glioma	0.0005	0.00473	CcSEcCtD
Imatinib—PIP4K2C—cerebellum—malignant glioma	0.000493	0.00714	CbGeAlD
Imatinib—ABL1—retina—malignant glioma	0.000492	0.00712	CbGeAlD
Imatinib—PTGS1—blood vessel—malignant glioma	0.000491	0.0071	CbGeAlD
Imatinib—CA3—central nervous system—malignant glioma	0.000482	0.00698	CbGeAlD
Imatinib—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000478	0.00452	CcSEcCtD
Imatinib—CA1—telencephalon—malignant glioma	0.000476	0.00689	CbGeAlD
Imatinib—Hyponatraemia—Carmustine—malignant glioma	0.000469	0.00444	CcSEcCtD
Imatinib—NQO2—midbrain—malignant glioma	0.000468	0.00678	CbGeAlD
Imatinib—Purpura—Temozolomide—malignant glioma	0.000468	0.00443	CcSEcCtD
Imatinib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000467	0.00442	CcSEcCtD
Imatinib—Nilotinib—CYP2B6—malignant glioma	0.000463	0.08	CrCbGaD
Imatinib—NQO2—spinal cord—malignant glioma	0.000457	0.00661	CbGeAlD
Imatinib—PDGFRA—spinal cord—malignant glioma	0.000456	0.0066	CbGeAlD
Imatinib—ABL1—telencephalon—malignant glioma	0.000453	0.00655	CbGeAlD
Imatinib—CA9—cerebellum—malignant glioma	0.000451	0.00653	CbGeAlD
Imatinib—Face oedema—Carmustine—malignant glioma	0.000451	0.00426	CcSEcCtD
Imatinib—CSF1R—medulla oblongata—malignant glioma	0.00045	0.00651	CbGeAlD
Imatinib—SLC22A1—telencephalon—malignant glioma	0.000436	0.00632	CbGeAlD
Imatinib—Face oedema—Temozolomide—malignant glioma	0.000436	0.00412	CcSEcCtD
Imatinib—CA14—cerebellum—malignant glioma	0.000428	0.00619	CbGeAlD
Imatinib—Hypokalaemia—Carmustine—malignant glioma	0.000425	0.00402	CcSEcCtD
Imatinib—ABL2—brain—malignant glioma	0.000423	0.00613	CbGeAlD
Imatinib—Dehydration—Temozolomide—malignant glioma	0.00042	0.00397	CcSEcCtD
Imatinib—CA7—brain—malignant glioma	0.000417	0.00604	CbGeAlD
Imatinib—Dry skin—Temozolomide—malignant glioma	0.000414	0.00391	CcSEcCtD
Imatinib—Muscular weakness—Carmustine—malignant glioma	0.000412	0.0039	CcSEcCtD
Imatinib—CSF1R—midbrain—malignant glioma	0.000411	0.00595	CbGeAlD
Imatinib—SLC47A1—medulla oblongata—malignant glioma	0.000411	0.00595	CbGeAlD
Imatinib—Hypokalaemia—Temozolomide—malignant glioma	0.000411	0.00389	CcSEcCtD
Imatinib—KIT—medulla oblongata—malignant glioma	0.000409	0.00591	CbGeAlD
Imatinib—Breast disorder—Temozolomide—malignant glioma	0.000408	0.00386	CcSEcCtD
Imatinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000406	0.00384	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000406	0.00384	CcSEcCtD
Imatinib—Dysphagia—Carmustine—malignant glioma	0.000404	0.00382	CcSEcCtD
Imatinib—CSF1R—spinal cord—malignant glioma	0.000401	0.00581	CbGeAlD
Imatinib—PIP4K2C—brain—malignant glioma	0.000401	0.0058	CbGeAlD
Imatinib—PDGFRB—medulla oblongata—malignant glioma	0.000399	0.00578	CbGeAlD
Imatinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000398	0.00377	CcSEcCtD
Imatinib—Muscular weakness—Temozolomide—malignant glioma	0.000398	0.00377	CcSEcCtD
Imatinib—Abdominal distension—Temozolomide—malignant glioma	0.000393	0.00371	CcSEcCtD
Imatinib—Dysphagia—Temozolomide—malignant glioma	0.00039	0.00369	CcSEcCtD
Imatinib—Pancytopenia—Carmustine—malignant glioma	0.000383	0.00363	CcSEcCtD
Imatinib—CA3—brain—malignant glioma	0.000383	0.00554	CbGeAlD
Imatinib—Sweating increased—Temozolomide—malignant glioma	0.00038	0.00359	CcSEcCtD
Imatinib—CA2—embryo—malignant glioma	0.000379	0.00549	CbGeAlD
Imatinib—Neutropenia—Carmustine—malignant glioma	0.000377	0.00357	CcSEcCtD
Imatinib—KIT—midbrain—malignant glioma	0.000373	0.00541	CbGeAlD
Imatinib—NQO2—central nervous system—malignant glioma	0.000371	0.00537	CbGeAlD
Imatinib—Pancytopenia—Temozolomide—malignant glioma	0.00037	0.0035	CcSEcCtD
Imatinib—PDGFRA—central nervous system—malignant glioma	0.00037	0.00535	CbGeAlD
Imatinib—SLC47A1—spinal cord—malignant glioma	0.000366	0.0053	CbGeAlD
Imatinib—PDGFRB—midbrain—malignant glioma	0.000365	0.00528	CbGeAlD
Imatinib—Neutropenia—Temozolomide—malignant glioma	0.000365	0.00345	CcSEcCtD
Imatinib—KIT—spinal cord—malignant glioma	0.000364	0.00527	CbGeAlD
Imatinib—Hyperglycaemia—Carmustine—malignant glioma	0.000364	0.00344	CcSEcCtD
Imatinib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000362	0.00343	CcSEcCtD
Imatinib—NQO2—cerebellum—malignant glioma	0.000362	0.00524	CbGeAlD
Imatinib—Pneumonia—Carmustine—malignant glioma	0.000362	0.00342	CcSEcCtD
Imatinib—PDGFRA—cerebellum—malignant glioma	0.000361	0.00523	CbGeAlD
Imatinib—Pollakiuria—Temozolomide—malignant glioma	0.00036	0.00341	CcSEcCtD
Imatinib—Erectile dysfunction—Temozolomide—malignant glioma	0.000359	0.0034	CcSEcCtD
Imatinib—Depression—Carmustine—malignant glioma	0.000359	0.00339	CcSEcCtD
Imatinib—Photosensitivity reaction—Temozolomide—malignant glioma	0.000356	0.00337	CcSEcCtD
Imatinib—PDGFRB—spinal cord—malignant glioma	0.000356	0.00515	CbGeAlD
Imatinib—ABL1—medulla oblongata—malignant glioma	0.000356	0.00515	CbGeAlD
Imatinib—Weight increased—Temozolomide—malignant glioma	0.000355	0.00336	CcSEcCtD
Imatinib—Renal failure—Carmustine—malignant glioma	0.000354	0.00335	CcSEcCtD
Imatinib—Weight decreased—Temozolomide—malignant glioma	0.000353	0.00334	CcSEcCtD
Imatinib—Neuropathy peripheral—Carmustine—malignant glioma	0.000353	0.00334	CcSEcCtD
Imatinib—Hyperglycaemia—Temozolomide—malignant glioma	0.000352	0.00333	CcSEcCtD
Imatinib—Stomatitis—Carmustine—malignant glioma	0.000351	0.00332	CcSEcCtD
Imatinib—Urinary tract infection—Carmustine—malignant glioma	0.00035	0.00331	CcSEcCtD
Imatinib—Pneumonia—Temozolomide—malignant glioma	0.00035	0.00331	CcSEcCtD
Imatinib—Infestation—Temozolomide—malignant glioma	0.000348	0.00329	CcSEcCtD
Imatinib—Infestation NOS—Temozolomide—malignant glioma	0.000348	0.00329	CcSEcCtD
Imatinib—CA14—brain—malignant glioma	0.000347	0.00503	CbGeAlD
Imatinib—CA2—brainstem—malignant glioma	0.000347	0.00503	CbGeAlD
Imatinib—Depression—Temozolomide—malignant glioma	0.000347	0.00328	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000345	0.00326	CcSEcCtD
Imatinib—CA12—central nervous system—malignant glioma	0.000341	0.00494	CbGeAlD
Imatinib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000341	0.00322	CcSEcCtD
Imatinib—Stomatitis—Temozolomide—malignant glioma	0.000339	0.00321	CcSEcCtD
Imatinib—Urinary tract infection—Temozolomide—malignant glioma	0.000338	0.0032	CcSEcCtD
Imatinib—CA2—retina—malignant glioma	0.000335	0.00485	CbGeAlD
Imatinib—ORM1—spinal cord—malignant glioma	0.000334	0.00483	CbGeAlD
Imatinib—CA1—spinal cord—malignant glioma	0.000333	0.00482	CbGeAlD
Imatinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000329	0.00311	CcSEcCtD
Imatinib—Sinusitis—Temozolomide—malignant glioma	0.000326	0.00309	CcSEcCtD
Imatinib—CSF1R—central nervous system—malignant glioma	0.000325	0.00471	CbGeAlD
Imatinib—ABL1—midbrain—malignant glioma	0.000325	0.00471	CbGeAlD
Imatinib—Haemoglobin—Carmustine—malignant glioma	0.000325	0.00307	CcSEcCtD
Imatinib—Haemorrhage—Carmustine—malignant glioma	0.000323	0.00306	CcSEcCtD
Imatinib—Hypoaesthesia—Carmustine—malignant glioma	0.000321	0.00304	CcSEcCtD
Imatinib—Oedema peripheral—Carmustine—malignant glioma	0.000318	0.00301	CcSEcCtD
Imatinib—CSF1R—cerebellum—malignant glioma	0.000318	0.00461	CbGeAlD
Imatinib—Connective tissue disorder—Carmustine—malignant glioma	0.000317	0.003	CcSEcCtD
Imatinib—ABL1—spinal cord—malignant glioma	0.000317	0.00459	CbGeAlD
Imatinib—Haemoglobin—Temozolomide—malignant glioma	0.000314	0.00297	CcSEcCtD
Imatinib—Hepatitis—Temozolomide—malignant glioma	0.000312	0.00295	CcSEcCtD
Imatinib—Haemorrhage—Temozolomide—malignant glioma	0.000312	0.00295	CcSEcCtD
Imatinib—Hypoaesthesia—Temozolomide—malignant glioma	0.000311	0.00294	CcSEcCtD
Imatinib—Pharyngitis—Temozolomide—malignant glioma	0.00031	0.00293	CcSEcCtD
Imatinib—Urinary tract disorder—Temozolomide—malignant glioma	0.000308	0.00292	CcSEcCtD
Imatinib—CA2—telencephalon—malignant glioma	0.000308	0.00446	CbGeAlD
Imatinib—Oedema peripheral—Temozolomide—malignant glioma	0.000308	0.00291	CcSEcCtD
Imatinib—Connective tissue disorder—Temozolomide—malignant glioma	0.000307	0.0029	CcSEcCtD
Imatinib—Urethral disorder—Temozolomide—malignant glioma	0.000306	0.00289	CcSEcCtD
Imatinib—Eye disorder—Carmustine—malignant glioma	0.000302	0.00286	CcSEcCtD
Imatinib—Flushing—Carmustine—malignant glioma	0.0003	0.00284	CcSEcCtD
Imatinib—SLC47A1—central nervous system—malignant glioma	0.000297	0.0043	CbGeAlD
Imatinib—KIT—central nervous system—malignant glioma	0.000296	0.00428	CbGeAlD
Imatinib—Erythema multiforme—Temozolomide—malignant glioma	0.000295	0.00279	CcSEcCtD
Imatinib—NQO2—brain—malignant glioma	0.000294	0.00426	CbGeAlD
Imatinib—PDGFRA—brain—malignant glioma	0.000294	0.00425	CbGeAlD
Imatinib—Eye disorder—Temozolomide—malignant glioma	0.000292	0.00276	CcSEcCtD
Imatinib—Tinnitus—Temozolomide—malignant glioma	0.000291	0.00275	CcSEcCtD
Imatinib—SLC47A1—cerebellum—malignant glioma	0.000291	0.00421	CbGeAlD
Imatinib—ABCB1—blood vessel—malignant glioma	0.00029	0.0042	CbGeAlD
Imatinib—Cardiac disorder—Temozolomide—malignant glioma	0.00029	0.00274	CcSEcCtD
Imatinib—Flushing—Temozolomide—malignant glioma	0.00029	0.00274	CcSEcCtD
Imatinib—KIT—cerebellum—malignant glioma	0.000289	0.00418	CbGeAlD
Imatinib—PDGFRB—central nervous system—malignant glioma	0.000289	0.00418	CbGeAlD
Imatinib—Arrhythmia—Carmustine—malignant glioma	0.000289	0.00273	CcSEcCtD
Imatinib—Alopecia—Carmustine—malignant glioma	0.000285	0.0027	CcSEcCtD
Imatinib—ABCG2—telencephalon—malignant glioma	0.000285	0.00413	CbGeAlD
Imatinib—Angiopathy—Temozolomide—malignant glioma	0.000283	0.00268	CcSEcCtD
Imatinib—Mental disorder—Carmustine—malignant glioma	0.000283	0.00268	CcSEcCtD
Imatinib—PDGFRB—cerebellum—malignant glioma	0.000282	0.00408	CbGeAlD
Imatinib—Immune system disorder—Temozolomide—malignant glioma	0.000282	0.00267	CcSEcCtD
Imatinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000281	0.00266	CcSEcCtD
Imatinib—Malnutrition—Carmustine—malignant glioma	0.000281	0.00266	CcSEcCtD
Imatinib—Erythema—Carmustine—malignant glioma	0.000281	0.00266	CcSEcCtD
Imatinib—Chills—Temozolomide—malignant glioma	0.00028	0.00265	CcSEcCtD
Imatinib—Alopecia—Temozolomide—malignant glioma	0.000276	0.00261	CcSEcCtD
Imatinib—Mental disorder—Temozolomide—malignant glioma	0.000274	0.00259	CcSEcCtD
Imatinib—Back pain—Carmustine—malignant glioma	0.000272	0.00257	CcSEcCtD
Imatinib—Malnutrition—Temozolomide—malignant glioma	0.000272	0.00257	CcSEcCtD
Imatinib—Erythema—Temozolomide—malignant glioma	0.000272	0.00257	CcSEcCtD
Imatinib—CA12—brain—malignant glioma	0.000271	0.00392	CbGeAlD
Imatinib—ORM1—central nervous system—malignant glioma	0.000271	0.00392	CbGeAlD
Imatinib—CA1—central nervous system—malignant glioma	0.00027	0.00391	CbGeAlD
Imatinib—Dysgeusia—Temozolomide—malignant glioma	0.000266	0.00252	CcSEcCtD
Imatinib—Vision blurred—Carmustine—malignant glioma	0.000265	0.00251	CcSEcCtD
Imatinib—Tremor—Carmustine—malignant glioma	0.000263	0.00249	CcSEcCtD
Imatinib—Back pain—Temozolomide—malignant glioma	0.000263	0.00249	CcSEcCtD
Imatinib—Anaemia—Carmustine—malignant glioma	0.00026	0.00246	CcSEcCtD
Imatinib—CSF1R—brain—malignant glioma	0.000258	0.00374	CbGeAlD
Imatinib—ABL1—central nervous system—malignant glioma	0.000257	0.00372	CbGeAlD
Imatinib—Vision blurred—Temozolomide—malignant glioma	0.000256	0.00242	CcSEcCtD
Imatinib—Tremor—Temozolomide—malignant glioma	0.000255	0.00241	CcSEcCtD
Imatinib—Ill-defined disorder—Temozolomide—malignant glioma	0.000252	0.00239	CcSEcCtD
Imatinib—Leukopenia—Carmustine—malignant glioma	0.000252	0.00238	CcSEcCtD
Imatinib—ABL1—cerebellum—malignant glioma	0.000251	0.00364	CbGeAlD
Imatinib—Anaemia—Temozolomide—malignant glioma	0.000251	0.00238	CcSEcCtD
Imatinib—Angioedema—Temozolomide—malignant glioma	0.000248	0.00235	CcSEcCtD
Imatinib—SLC22A1—central nervous system—malignant glioma	0.000248	0.00359	CbGeAlD
Imatinib—Malaise—Temozolomide—malignant glioma	0.000245	0.00232	CcSEcCtD
Imatinib—Vertigo—Temozolomide—malignant glioma	0.000244	0.00231	CcSEcCtD
Imatinib—Convulsion—Carmustine—malignant glioma	0.000244	0.0023	CcSEcCtD
Imatinib—Leukopenia—Temozolomide—malignant glioma	0.000243	0.0023	CcSEcCtD
Imatinib—Hypertension—Carmustine—malignant glioma	0.000243	0.0023	CcSEcCtD
Imatinib—CA2—medulla oblongata—malignant glioma	0.000242	0.00351	CbGeAlD
Imatinib—Palpitations—Temozolomide—malignant glioma	0.00024	0.00227	CcSEcCtD
Imatinib—Myalgia—Carmustine—malignant glioma	0.000239	0.00226	CcSEcCtD
Imatinib—Chest pain—Carmustine—malignant glioma	0.000239	0.00226	CcSEcCtD
Imatinib—Anxiety—Carmustine—malignant glioma	0.000239	0.00226	CcSEcCtD
Imatinib—PTGS1—telencephalon—malignant glioma	0.000238	0.00345	CbGeAlD
Imatinib—Cough—Temozolomide—malignant glioma	0.000237	0.00224	CcSEcCtD
Imatinib—SLC47A1—brain—malignant glioma	0.000236	0.00342	CbGeAlD
Imatinib—Convulsion—Temozolomide—malignant glioma	0.000235	0.00223	CcSEcCtD
Imatinib—KIT—brain—malignant glioma	0.000235	0.0034	CbGeAlD
Imatinib—Hypertension—Temozolomide—malignant glioma	0.000235	0.00222	CcSEcCtD
Imatinib—Confusional state—Carmustine—malignant glioma	0.000231	0.00219	CcSEcCtD
Imatinib—Myalgia—Temozolomide—malignant glioma	0.000231	0.00219	CcSEcCtD
Imatinib—Arthralgia—Temozolomide—malignant glioma	0.000231	0.00219	CcSEcCtD
Imatinib—Anxiety—Temozolomide—malignant glioma	0.000231	0.00218	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00023	0.00217	CcSEcCtD
Imatinib—Oedema—Carmustine—malignant glioma	0.00023	0.00217	CcSEcCtD
Imatinib—PDGFRB—brain—malignant glioma	0.000229	0.00332	CbGeAlD
Imatinib—Discomfort—Temozolomide—malignant glioma	0.000229	0.00216	CcSEcCtD
Imatinib—Infection—Carmustine—malignant glioma	0.000228	0.00216	CcSEcCtD
Imatinib—Dry mouth—Temozolomide—malignant glioma	0.000226	0.00214	CcSEcCtD
Imatinib—Thrombocytopenia—Carmustine—malignant glioma	0.000225	0.00213	CcSEcCtD
Imatinib—ABCG2—medulla oblongata—malignant glioma	0.000224	0.00325	CbGeAlD
Imatinib—Tachycardia—Carmustine—malignant glioma	0.000224	0.00212	CcSEcCtD
Imatinib—Confusional state—Temozolomide—malignant glioma	0.000224	0.00212	CcSEcCtD
Imatinib—Anaphylactic shock—Temozolomide—malignant glioma	0.000222	0.0021	CcSEcCtD
Imatinib—Oedema—Temozolomide—malignant glioma	0.000222	0.0021	CcSEcCtD
Imatinib—CA2—midbrain—malignant glioma	0.000221	0.0032	CbGeAlD
Imatinib—CYP2D6—brainstem—malignant glioma	0.00022	0.00319	CbGeAlD
Imatinib—Infection—Temozolomide—malignant glioma	0.00022	0.00208	CcSEcCtD
Imatinib—Anorexia—Carmustine—malignant glioma	0.000219	0.00207	CcSEcCtD
Imatinib—Nervous system disorder—Temozolomide—malignant glioma	0.000218	0.00206	CcSEcCtD
Imatinib—Thrombocytopenia—Temozolomide—malignant glioma	0.000217	0.00205	CcSEcCtD
Imatinib—CA2—spinal cord—malignant glioma	0.000216	0.00313	CbGeAlD
Imatinib—Skin disorder—Temozolomide—malignant glioma	0.000215	0.00204	CcSEcCtD
Imatinib—CA1—brain—malignant glioma	0.000215	0.00311	CbGeAlD
Imatinib—Hypotension—Carmustine—malignant glioma	0.000214	0.00203	CcSEcCtD
Imatinib—Hyperhidrosis—Temozolomide—malignant glioma	0.000214	0.00203	CcSEcCtD
Imatinib—Anorexia—Temozolomide—malignant glioma	0.000211	0.002	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000209	0.00198	CcSEcCtD
Imatinib—Insomnia—Carmustine—malignant glioma	0.000208	0.00196	CcSEcCtD
Imatinib—Paraesthesia—Carmustine—malignant glioma	0.000206	0.00195	CcSEcCtD
Imatinib—ABCG2—midbrain—malignant glioma	0.000205	0.00297	CbGeAlD
Imatinib—Dyspnoea—Carmustine—malignant glioma	0.000205	0.00194	CcSEcCtD
Imatinib—ABL1—brain—malignant glioma	0.000204	0.00296	CbGeAlD
Imatinib—Somnolence—Carmustine—malignant glioma	0.000204	0.00193	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000202	0.00191	CcSEcCtD
Imatinib—Insomnia—Temozolomide—malignant glioma	0.000201	0.0019	CcSEcCtD
Imatinib—ABCG2—spinal cord—malignant glioma	0.0002	0.0029	CbGeAlD
Imatinib—Decreased appetite—Carmustine—malignant glioma	0.0002	0.00189	CcSEcCtD
Imatinib—Paraesthesia—Temozolomide—malignant glioma	0.000199	0.00188	CcSEcCtD
Imatinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000198	0.00187	CcSEcCtD
Imatinib—Dyspnoea—Temozolomide—malignant glioma	0.000198	0.00187	CcSEcCtD
Imatinib—Somnolence—Temozolomide—malignant glioma	0.000197	0.00187	CcSEcCtD
Imatinib—SLC22A1—brain—malignant glioma	0.000197	0.00285	CbGeAlD
Imatinib—Constipation—Carmustine—malignant glioma	0.000196	0.00186	CcSEcCtD
Imatinib—Pain—Carmustine—malignant glioma	0.000196	0.00186	CcSEcCtD
Imatinib—CYP2D6—telencephalon—malignant glioma	0.000196	0.00283	CbGeAlD
Imatinib—Dyspepsia—Temozolomide—malignant glioma	0.000195	0.00185	CcSEcCtD
Imatinib—Decreased appetite—Temozolomide—malignant glioma	0.000193	0.00182	CcSEcCtD
Imatinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000191	0.00181	CcSEcCtD
Imatinib—Fatigue—Temozolomide—malignant glioma	0.000191	0.00181	CcSEcCtD
Imatinib—Constipation—Temozolomide—malignant glioma	0.00019	0.00179	CcSEcCtD
Imatinib—Pain—Temozolomide—malignant glioma	0.00019	0.00179	CcSEcCtD
Imatinib—Feeling abnormal—Carmustine—malignant glioma	0.000189	0.00179	CcSEcCtD
Imatinib—ALB—brain—malignant glioma	0.000189	0.00273	CbGeAlD
Imatinib—Gastrointestinal pain—Carmustine—malignant glioma	0.000188	0.00178	CcSEcCtD
Imatinib—Feeling abnormal—Temozolomide—malignant glioma	0.000183	0.00173	CcSEcCtD
Imatinib—Abdominal pain—Carmustine—malignant glioma	0.000181	0.00172	CcSEcCtD
Imatinib—Body temperature increased—Carmustine—malignant glioma	0.000181	0.00172	CcSEcCtD
Imatinib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000181	0.00172	CcSEcCtD
Imatinib—Urticaria—Temozolomide—malignant glioma	0.000176	0.00167	CcSEcCtD
Imatinib—Abdominal pain—Temozolomide—malignant glioma	0.000175	0.00166	CcSEcCtD
Imatinib—Body temperature increased—Temozolomide—malignant glioma	0.000175	0.00166	CcSEcCtD
Imatinib—CA2—central nervous system—malignant glioma	0.000175	0.00254	CbGeAlD
Imatinib—ABCB1—embryo—malignant glioma	0.000173	0.00251	CbGeAlD
Imatinib—CA2—cerebellum—malignant glioma	0.000171	0.00248	CbGeAlD
Imatinib—Hypersensitivity—Carmustine—malignant glioma	0.000169	0.0016	CcSEcCtD
Imatinib—PTGS1—spinal cord—malignant glioma	0.000167	0.00241	CbGeAlD
Imatinib—Asthenia—Carmustine—malignant glioma	0.000165	0.00156	CcSEcCtD
Imatinib—Hypersensitivity—Temozolomide—malignant glioma	0.000163	0.00155	CcSEcCtD
Imatinib—Asthenia—Temozolomide—malignant glioma	0.000159	0.00151	CcSEcCtD
Imatinib—ABCG2—cerebellum—malignant glioma	0.000159	0.0023	CbGeAlD
Imatinib—Diarrhoea—Carmustine—malignant glioma	0.000157	0.00149	CcSEcCtD
Imatinib—Pruritus—Temozolomide—malignant glioma	0.000157	0.00148	CcSEcCtD
Imatinib—ABCB1—retina—malignant glioma	0.000153	0.00222	CbGeAlD
Imatinib—Dizziness—Carmustine—malignant glioma	0.000152	0.00144	CcSEcCtD
Imatinib—Diarrhoea—Temozolomide—malignant glioma	0.000152	0.00144	CcSEcCtD
Imatinib—Dizziness—Temozolomide—malignant glioma	0.000147	0.00139	CcSEcCtD
Imatinib—Vomiting—Carmustine—malignant glioma	0.000146	0.00138	CcSEcCtD
Imatinib—Rash—Carmustine—malignant glioma	0.000145	0.00137	CcSEcCtD
Imatinib—Dermatitis—Carmustine—malignant glioma	0.000145	0.00137	CcSEcCtD
Imatinib—Headache—Carmustine—malignant glioma	0.000144	0.00136	CcSEcCtD
Imatinib—Vomiting—Temozolomide—malignant glioma	0.000141	0.00133	CcSEcCtD
Imatinib—ABCB1—telencephalon—malignant glioma	0.000141	0.00204	CbGeAlD
Imatinib—Rash—Temozolomide—malignant glioma	0.00014	0.00132	CcSEcCtD
Imatinib—Dermatitis—Temozolomide—malignant glioma	0.00014	0.00132	CcSEcCtD
Imatinib—CA2—brain—malignant glioma	0.000139	0.00201	CbGeAlD
Imatinib—Headache—Temozolomide—malignant glioma	0.000139	0.00131	CcSEcCtD
Imatinib—Nausea—Carmustine—malignant glioma	0.000136	0.00129	CcSEcCtD
Imatinib—PTGS1—central nervous system—malignant glioma	0.000135	0.00196	CbGeAlD
Imatinib—Nausea—Temozolomide—malignant glioma	0.000132	0.00125	CcSEcCtD
Imatinib—ABCG2—brain—malignant glioma	0.000129	0.00186	CbGeAlD
Imatinib—CYP3A4—central nervous system—malignant glioma	0.000113	0.00164	CbGeAlD
Imatinib—CYP2D6—central nervous system—malignant glioma	0.000111	0.00161	CbGeAlD
Imatinib—ABCB1—medulla oblongata—malignant glioma	0.000111	0.0016	CbGeAlD
Imatinib—CYP2D6—cerebellum—malignant glioma	0.000109	0.00157	CbGeAlD
Imatinib—PTGS1—brain—malignant glioma	0.000107	0.00156	CbGeAlD
Imatinib—ABCB1—midbrain—malignant glioma	0.000101	0.00146	CbGeAlD
Imatinib—ABCB1—spinal cord—malignant glioma	9.86e-05	0.00143	CbGeAlD
Imatinib—CYP2D6—brain—malignant glioma	8.83e-05	0.00128	CbGeAlD
Imatinib—ABCB1—central nervous system—malignant glioma	8e-05	0.00116	CbGeAlD
Imatinib—ABCB1—cerebellum—malignant glioma	7.82e-05	0.00113	CbGeAlD
Imatinib—ABCB1—brain—malignant glioma	6.35e-05	0.00092	CbGeAlD
Imatinib—ABCG2—Metabolism—PIK3CD—malignant glioma	2.61e-06	1.72e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KRAS—malignant glioma	2.6e-06	1.71e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—AKT1—malignant glioma	2.6e-06	1.71e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—malignant glioma	2.59e-06	1.71e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CD—malignant glioma	2.59e-06	1.71e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2C18—malignant glioma	2.59e-06	1.7e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CD—malignant glioma	2.58e-06	1.7e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	2.58e-06	1.7e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KRAS—malignant glioma	2.57e-06	1.7e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CD80—malignant glioma	2.57e-06	1.69e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CG—malignant glioma	2.56e-06	1.69e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—APC—malignant glioma	2.56e-06	1.69e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—PIK3CA—malignant glioma	2.56e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	2.56e-06	1.69e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—AKT1—malignant glioma	2.55e-06	1.68e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS1—malignant glioma	2.54e-06	1.67e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGF—malignant glioma	2.53e-06	1.67e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	2.53e-06	1.67e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTPN11—malignant glioma	2.52e-06	1.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MDM2—malignant glioma	2.52e-06	1.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KRAS—malignant glioma	2.51e-06	1.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—malignant glioma	2.51e-06	1.65e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CD—malignant glioma	2.51e-06	1.65e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RAF1—malignant glioma	2.51e-06	1.65e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CASP3—malignant glioma	2.5e-06	1.65e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PIK3CA—malignant glioma	2.5e-06	1.65e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—malignant glioma	2.5e-06	1.64e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—malignant glioma	2.5e-06	1.64e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—malignant glioma	2.49e-06	1.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—malignant glioma	2.48e-06	1.63e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTEN—malignant glioma	2.48e-06	1.63e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NCOR1—malignant glioma	2.47e-06	1.63e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—malignant glioma	2.46e-06	1.62e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—malignant glioma	2.45e-06	1.61e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CB—malignant glioma	2.45e-06	1.61e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	2.45e-06	1.61e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTEN—malignant glioma	2.42e-06	1.6e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTP1—malignant glioma	2.41e-06	1.59e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—BRAF—malignant glioma	2.41e-06	1.59e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CD—malignant glioma	2.41e-06	1.59e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—malignant glioma	2.39e-06	1.57e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—malignant glioma	2.37e-06	1.56e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—malignant glioma	2.36e-06	1.56e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—BCHE—malignant glioma	2.36e-06	1.56e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTP1—malignant glioma	2.35e-06	1.55e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—malignant glioma	2.35e-06	1.55e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—malignant glioma	2.35e-06	1.55e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTEN—malignant glioma	2.35e-06	1.55e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAT—malignant glioma	2.35e-06	1.55e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT2—malignant glioma	2.35e-06	1.55e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CAV1—malignant glioma	2.34e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC5A5—malignant glioma	2.33e-06	1.54e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—malignant glioma	2.32e-06	1.53e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—malignant glioma	2.31e-06	1.52e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—malignant glioma	2.31e-06	1.52e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—malignant glioma	2.3e-06	1.51e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAT—malignant glioma	2.29e-06	1.51e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CB—malignant glioma	2.28e-06	1.5e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CB—malignant glioma	2.26e-06	1.49e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—malignant glioma	2.26e-06	1.49e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CD—malignant glioma	2.25e-06	1.49e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CB—malignant glioma	2.25e-06	1.48e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—malignant glioma	2.25e-06	1.48e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—malignant glioma	2.25e-06	1.48e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—malignant glioma	2.25e-06	1.48e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—malignant glioma	2.24e-06	1.48e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—malignant glioma	2.24e-06	1.48e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—malignant glioma	2.24e-06	1.47e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—malignant glioma	2.23e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	2.23e-06	1.47e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—malignant glioma	2.22e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTP1—malignant glioma	2.22e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NCOR1—malignant glioma	2.22e-06	1.46e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—malignant glioma	2.21e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	2.21e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—malignant glioma	2.2e-06	1.45e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CB—malignant glioma	2.19e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	2.19e-06	1.44e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—malignant glioma	2.17e-06	1.43e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—malignant glioma	2.17e-06	1.43e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NCOR1—malignant glioma	2.16e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAT—malignant glioma	2.16e-06	1.42e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FGF2—malignant glioma	2.16e-06	1.42e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAT—malignant glioma	2.14e-06	1.41e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—malignant glioma	2.13e-06	1.41e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—malignant glioma	2.13e-06	1.4e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CG—malignant glioma	2.13e-06	1.4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—malignant glioma	2.13e-06	1.4e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—malignant glioma	2.12e-06	1.4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—malignant glioma	2.12e-06	1.39e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—malignant glioma	2.11e-06	1.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—malignant glioma	2.1e-06	1.38e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CB—malignant glioma	2.1e-06	1.38e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—malignant glioma	2.09e-06	1.38e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTT1—malignant glioma	2.09e-06	1.38e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—malignant glioma	2.08e-06	1.37e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—malignant glioma	2.06e-06	1.36e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—malignant glioma	2.05e-06	1.35e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—malignant glioma	2.04e-06	1.35e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—malignant glioma	2.04e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NCOR1—malignant glioma	2.04e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NCOR1—malignant glioma	2.02e-06	1.33e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MDM2—malignant glioma	2.02e-06	1.33e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—malignant glioma	2.02e-06	1.33e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—malignant glioma	2.02e-06	1.33e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—malignant glioma	2.01e-06	1.33e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAV1—malignant glioma	2.01e-06	1.33e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RAF1—malignant glioma	2.01e-06	1.33e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—malignant glioma	1.99e-06	1.31e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—malignant glioma	1.97e-06	1.3e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—malignant glioma	1.97e-06	1.3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CB—malignant glioma	1.96e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS1—malignant glioma	1.96e-06	1.29e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—malignant glioma	1.95e-06	1.29e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—malignant glioma	1.95e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—malignant glioma	1.95e-06	1.28e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—malignant glioma	1.95e-06	1.28e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—malignant glioma	1.93e-06	1.27e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.92e-06	1.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—malignant glioma	1.91e-06	1.26e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—malignant glioma	1.91e-06	1.26e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.91e-06	1.26e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—malignant glioma	1.9e-06	1.26e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—malignant glioma	1.89e-06	1.25e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—malignant glioma	1.89e-06	1.25e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—malignant glioma	1.89e-06	1.24e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—malignant glioma	1.89e-06	1.24e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—malignant glioma	1.88e-06	1.24e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CD—malignant glioma	1.87e-06	1.23e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—malignant glioma	1.86e-06	1.23e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—malignant glioma	1.85e-06	1.22e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—malignant glioma	1.84e-06	1.21e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—malignant glioma	1.83e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAT—malignant glioma	1.83e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—BCHE—malignant glioma	1.82e-06	1.2e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—malignant glioma	1.81e-06	1.2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—malignant glioma	1.81e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAV1—malignant glioma	1.81e-06	1.19e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—malignant glioma	1.8e-06	1.19e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—malignant glioma	1.8e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.8e-06	1.19e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—malignant glioma	1.77e-06	1.17e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAV1—malignant glioma	1.76e-06	1.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—malignant glioma	1.76e-06	1.16e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—malignant glioma	1.75e-06	1.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—malignant glioma	1.74e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NCOR1—malignant glioma	1.73e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.73e-06	1.14e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—malignant glioma	1.73e-06	1.14e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—malignant glioma	1.72e-06	1.13e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—malignant glioma	1.71e-06	1.13e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—malignant glioma	1.71e-06	1.13e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—malignant glioma	1.7e-06	1.12e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—malignant glioma	1.69e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAV1—malignant glioma	1.66e-06	1.09e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—malignant glioma	1.66e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAV1—malignant glioma	1.65e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—malignant glioma	1.65e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CB—malignant glioma	1.63e-06	1.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—malignant glioma	1.62e-06	1.07e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—malignant glioma	1.62e-06	1.06e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CD—malignant glioma	1.61e-06	1.06e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—malignant glioma	1.61e-06	1.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—malignant glioma	1.6e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—malignant glioma	1.59e-06	1.05e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.57e-06	1.04e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—malignant glioma	1.55e-06	1.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—malignant glioma	1.53e-06	1.01e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—malignant glioma	1.52e-06	1e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—malignant glioma	1.51e-06	9.97e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—malignant glioma	1.51e-06	9.97e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—malignant glioma	1.5e-06	9.89e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—malignant glioma	1.49e-06	9.83e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—malignant glioma	1.46e-06	9.62e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—malignant glioma	1.45e-06	9.55e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—malignant glioma	1.45e-06	9.54e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CD—malignant glioma	1.45e-06	9.53e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—malignant glioma	1.44e-06	9.51e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—malignant glioma	1.43e-06	9.42e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CD—malignant glioma	1.41e-06	9.3e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAT—malignant glioma	1.41e-06	9.3e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—malignant glioma	1.41e-06	9.3e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—malignant glioma	1.41e-06	9.29e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAV1—malignant glioma	1.41e-06	9.27e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CB—malignant glioma	1.4e-06	9.25e-06	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—malignant glioma	1.4e-06	9.21e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—malignant glioma	1.39e-06	9.17e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—malignant glioma	1.39e-06	9.14e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—malignant glioma	1.38e-06	9.09e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—malignant glioma	1.38e-06	9.06e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—malignant glioma	1.37e-06	9.05e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—malignant glioma	1.35e-06	8.92e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.34e-06	8.86e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—malignant glioma	1.33e-06	8.78e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOR1—malignant glioma	1.33e-06	8.78e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CD—malignant glioma	1.33e-06	8.77e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CD—malignant glioma	1.32e-06	8.69e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—malignant glioma	1.3e-06	8.59e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—malignant glioma	1.28e-06	8.45e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—malignant glioma	1.28e-06	8.43e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CB—malignant glioma	1.26e-06	8.31e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—malignant glioma	1.25e-06	8.23e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—malignant glioma	1.24e-06	8.15e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CB—malignant glioma	1.23e-06	8.11e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—malignant glioma	1.22e-06	8.03e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—malignant glioma	1.22e-06	8.03e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—malignant glioma	1.21e-06	8e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—malignant glioma	1.2e-06	7.89e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CB—malignant glioma	1.16e-06	7.64e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—malignant glioma	1.16e-06	7.63e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CB—malignant glioma	1.15e-06	7.57e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—malignant glioma	1.15e-06	7.57e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—malignant glioma	1.14e-06	7.51e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—malignant glioma	1.13e-06	7.47e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CD—malignant glioma	1.13e-06	7.43e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—malignant glioma	1.12e-06	7.4e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—malignant glioma	1.12e-06	7.39e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—malignant glioma	1.09e-06	7.18e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—malignant glioma	1.09e-06	7.18e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAV1—malignant glioma	1.09e-06	7.16e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—malignant glioma	1.06e-06	7.01e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—malignant glioma	1.05e-06	6.89e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—malignant glioma	1e-06	6.6e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—malignant glioma	9.94e-07	6.55e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—malignant glioma	9.93e-07	6.55e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	9.89e-07	6.52e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CB—malignant glioma	9.82e-07	6.47e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—malignant glioma	9.78e-07	6.45e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—malignant glioma	9.73e-07	6.41e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—malignant glioma	9.55e-07	6.29e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	8.7e-07	5.73e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—malignant glioma	8.56e-07	5.64e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—malignant glioma	8.49e-07	5.59e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—malignant glioma	8.12e-07	5.35e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—malignant glioma	7.69e-07	5.06e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	7.58e-07	5e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—malignant glioma	7.51e-07	4.95e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—malignant glioma	7.5e-07	4.94e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—malignant glioma	7.07e-07	4.66e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—malignant glioma	7.01e-07	4.62e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—malignant glioma	6.99e-07	4.61e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—malignant glioma	6.55e-07	4.32e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—malignant glioma	6.28e-07	4.14e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—malignant glioma	6.13e-07	4.04e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—malignant glioma	5.99e-07	3.95e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—malignant glioma	5.77e-07	3.81e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—malignant glioma	5.72e-07	3.77e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—malignant glioma	4.89e-07	3.22e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	4.62e-07	3.05e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—malignant glioma	3.78e-07	2.49e-06	CbGpPWpGaD
